EA201270808A1 - Новые формы рифаксимина и их применение - Google Patents

Новые формы рифаксимина и их применение

Info

Publication number
EA201270808A1
EA201270808A1 EA201270808A EA201270808A EA201270808A1 EA 201270808 A1 EA201270808 A1 EA 201270808A1 EA 201270808 A EA201270808 A EA 201270808A EA 201270808 A EA201270808 A EA 201270808A EA 201270808 A1 EA201270808 A1 EA 201270808A1
Authority
EA
Eurasian Patent Office
Prior art keywords
rifaximine
application
rifaximin
new forms
piperazine
Prior art date
Application number
EA201270808A
Other languages
English (en)
Other versions
EA022490B1 (ru
Inventor
Идуо У
Стефан Д. Парент
Натан Карл Шультайсс
Мелани Джанелле Бевилль
Петинка Влахов
Трэвис Л. Хьюстон
Original Assignee
Саликс Фармасьютикалс, Лтд.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Саликс Фармасьютикалс, Лтд. filed Critical Саликс Фармасьютикалс, Лтд.
Publication of EA201270808A1 publication Critical patent/EA201270808A1/ru
Publication of EA022490B1 publication Critical patent/EA022490B1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C07D491/048—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/22—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains four or more hetero rings

Abstract

Изобретение относится к новым полиморфным формам рифаксимина: форме рифаксимина каппа, тета, смешанным кристаллам рифаксимина-пиперазина 1 и смешанным кристаллам рифаксимина-пиперазина 2, способам их получения и их применению в качестве медицинских препаратов и способам их терапевтического применения.
EA201270808A 2010-06-03 2011-06-03 Новые формы рифаксимина и их применение EA022490B1 (ru)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US35128110P 2010-06-03 2010-06-03
US35750510P 2010-06-22 2010-06-22
US36324110P 2010-07-10 2010-07-10
US36351110P 2010-07-12 2010-07-12
US36718510P 2010-07-23 2010-07-23
US41659310P 2010-11-23 2010-11-23
PCT/US2011/039085 WO2011153444A1 (en) 2010-06-03 2011-06-03 New forms of rifaximin and uses thereof

Publications (2)

Publication Number Publication Date
EA201270808A1 true EA201270808A1 (ru) 2013-04-30
EA022490B1 EA022490B1 (ru) 2016-01-29

Family

ID=45067089

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201270808A EA022490B1 (ru) 2010-06-03 2011-06-03 Новые формы рифаксимина и их применение

Country Status (17)

Country Link
US (2) US8513275B2 (ru)
EP (1) EP2575464A4 (ru)
JP (1) JP2013527246A (ru)
KR (1) KR20130086338A (ru)
CN (1) CN103269587A (ru)
AU (1) AU2011261283B2 (ru)
BR (1) BR112012030783A2 (ru)
CA (1) CA2800668A1 (ru)
CR (1) CR20120620A (ru)
EA (1) EA022490B1 (ru)
IL (1) IL222900A (ru)
MX (1) MX2012013945A (ru)
NZ (2) NZ603590A (ru)
SG (2) SG10201507035UA (ru)
TN (1) TN2012000533A1 (ru)
WO (1) WO2011153444A1 (ru)
ZA (1) ZA201208770B (ru)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI1698630T1 (sl) 2005-03-03 2015-01-30 Alfa Wassermann S.P.A. Nove polimorfne oblike rifaksimina, postopki za njihovo pripravo in njihova uporaba v medicinskih pripravkih
CN102015725B (zh) 2008-02-25 2014-10-22 萨利克斯药品有限公司 利福昔明的多种形式及其用途
US8486956B2 (en) 2008-02-25 2013-07-16 Salix Pharmaceuticals, Ltd Forms of rifaximin and uses thereof
US9018684B2 (en) 2009-11-23 2015-04-28 California Institute Of Technology Chemical sensing and/or measuring devices and methods
IT1398550B1 (it) 2010-03-05 2013-03-01 Alfa Wassermann Spa Formulazioni comprendenti rifaximina utili per ottenere un effetto prolungato nel tempo
EP2544660B1 (en) * 2010-03-10 2018-06-13 Lupin Limited Rifaximin ready-to-use suspension
JP6076267B2 (ja) * 2011-02-11 2017-02-08 サリックス ファーマスーティカルズ，リミテッド リファキシミンの形態およびその使用
AU2012251385A1 (en) * 2011-05-02 2013-11-21 Ranbaxy Laboratories Limited Rifaximin dimethylformamide solvate
ITBO20110461A1 (it) 2011-07-29 2013-01-30 Alfa Wassermann Spa Composizioni farmaceutiche comprendenti rifaximina, processi per la loro preparazione e loro uso nel trattamento di infezioni vaginali.
US20130184302A1 (en) 2011-11-02 2013-07-18 Enoch Bortey Methods for treating irritable bowel syndrome (ibs) and infections
US9359374B2 (en) 2012-06-13 2016-06-07 Apotex Pharmachem Inc. Polymorphic forms of rifaximin
ITBO20120368A1 (it) 2012-07-06 2014-01-07 Alfa Wassermann Spa Composizioni comprendenti rifaximina e amminoacidi, cristalli di rifaximina derivanti da tali composizioni e loro uso.
MX2015002934A (es) * 2012-09-13 2015-10-29 Salix Pharmaceuticals Inc Metodos de administracion de rifaximina para perdida de peso y tratamiento de obesidad.
WO2014140988A1 (en) 2013-03-15 2014-09-18 Alfa Wassermann S.P.A. Rifaximin for use in the treating of vaginal infections.
WO2014140995A2 (en) 2013-03-15 2014-09-18 Alfa Wassermann S.P.A. Method for diagnosing vaginal infections
ES2829285T3 (es) 2013-04-12 2021-05-31 Alfasigma Spa Administración de AINE y composiciones, métodos y sistemas relacionados
ITMI20131307A1 (it) * 2013-08-02 2015-02-02 A M S A Anonima Materie Sint & Affini S P A Processo per la preparazione di refaximina k
EP2927235B1 (en) 2014-03-31 2017-02-08 Euticals S.P.A. Polymorphic mixture of rifaximin and its use for the preparation of solid formulations
MX2016014329A (es) 2014-05-04 2017-02-23 Salix Pharmaceuticals Inc Microbiota ibs y sus usos.
NZ723571A (en) * 2014-05-12 2020-02-28 Alfasigma Spa New solvated crystal form of rifaximin, production, compositions and uses thereof

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7927613B2 (en) * 2002-02-15 2011-04-19 University Of South Florida Pharmaceutical co-crystal compositions
US7902206B2 (en) * 2003-11-07 2011-03-08 Alfa Wassermann, S.P.A. Polymorphic forms α, β and γ of rifaximin
ITMI20032144A1 (it) * 2003-11-07 2005-05-08 Alfa Wassermann Spa Forme polimorfe di rifaximina, processi per ottenerle e
JP2007516259A (ja) * 2003-12-09 2007-06-21 メッドクリスタルフォームズ、エルエルシー 活性剤との混合相共結晶の調製方法
JP5017103B2 (ja) * 2004-06-17 2012-09-05 トランスフオーム・フアーマシユーチカルズ・インコーポレーテツド 薬剤共結晶組成物および関連した使用方法
US7709634B2 (en) * 2007-09-20 2010-05-04 Apotex Pharmachem Inc. Amorphous form of rifaximin and processes for its preparation
US8486956B2 (en) * 2008-02-25 2013-07-16 Salix Pharmaceuticals, Ltd Forms of rifaximin and uses thereof
CN102015725B (zh) * 2008-02-25 2014-10-22 萨利克斯药品有限公司 利福昔明的多种形式及其用途

Also Published As

Publication number Publication date
WO2011153444A1 (en) 2011-12-08
NZ710780A (en) 2017-02-24
SG10201507035UA (en) 2015-10-29
KR20130086338A (ko) 2013-08-01
CR20120620A (es) 2014-05-23
US8815888B2 (en) 2014-08-26
AU2011261283B2 (en) 2015-05-14
EA022490B1 (ru) 2016-01-29
CA2800668A1 (en) 2011-12-08
CN103269587A (zh) 2013-08-28
ZA201208770B (en) 2013-07-31
US20130317225A1 (en) 2013-11-28
NZ603590A (en) 2015-08-28
SG185490A1 (en) 2012-12-28
JP2013527246A (ja) 2013-06-27
EP2575464A1 (en) 2013-04-10
TN2012000533A1 (en) 2014-04-01
EP2575464A4 (en) 2013-10-02
AU2011261283A1 (en) 2012-12-06
US8513275B2 (en) 2013-08-20
BR112012030783A2 (pt) 2015-09-29
IL222900A (en) 2017-11-30
IL222900A0 (en) 2012-12-31
US20120108620A1 (en) 2012-05-03
MX2012013945A (es) 2013-05-06

Similar Documents

Publication Publication Date Title
EA201270808A1 (ru) Новые формы рифаксимина и их применение
EA201370018A1 (ru) Составы рифаксимина и их применение
EA201270722A1 (ru) Формы рифаксимина и их применение
EA201201357A1 (ru) Антитела к cd40
WO2012118812A3 (en) Substituted 6,5-fused bicyclic heteroaryl compounds
EA201691070A1 (ru) Новые трициклические соединения в качестве противораковых средств
EA201390772A1 (ru) Новые соли и полиморфные формы афатиниба
EA201101182A1 (ru) Новые аминоазагетероциклические карбоксамиды
EA201890333A1 (ru) Противовирусные соединения
EA201400412A1 (ru) ЗАМЕЩЕННЫЕ БЕНЗИЛИНДАЗОЛЫ ДЛЯ ПРИМЕНЕНИЯ В КАЧЕСТВЕ ИНГИБИТОРОВ Bub1 КИНАЗЫ ДЛЯ ЛЕЧЕНИЯ ГИПЕРПРОЛИФЕРАТИВНЫХ ЗАБОЛЕВАНИЙ
EA201391644A1 (ru) Частично насыщенные трициклические соединения и способы их получения и применения
MY183637A (en) Compounds and uses thereof for the modulation of hemoglobin
EA201492216A1 (ru) Ингибиторы бромодомена и их применение
EA201390803A1 (ru) Ингибиторы бромодомена и их применение
EA201500298A1 (ru) Алкоксипиразолы в качестве активаторов растворимой гуанилатциклазы
EA201491766A1 (ru) Соединения для лечения спинальной мышечной атрофии
EA201790963A1 (ru) Противовирусные соединения
EA201390908A1 (ru) Производные бицикло[3.2.1]октиламида и их применение
EA201500182A1 (ru) 4-МЕТИЛ-2,3,5,9,9b-ПЕНТААЗАЦИКЛОПЕНТА[a]НАФТАЛИНЫ
MX347734B (es) Anticuerpos anti-s100a4 y usos aplicaciones terapéuticas.
EA201490471A1 (ru) Пиридазиноновые соединения и их применение в качестве ингибиторов daao
EA201491028A8 (ru) Способ получения замещенных 5-фтор-1н-пиразолопиридинов
EA201400567A1 (ru) НОВЫЕ ПРОИЗВОДНЫЕ ЦИКЛОГЕКСИЛАМИНА, ОБЛАДАЮЩИЕ АГОНИСТИЧЕСКОЙ АКТИВНОСТЬЮ ПО ОТНОШЕНИЮ К β2 АДРЕНЕРГИЧЕСКОМУ РЕЦЕПТОРУ И АНТАГОНИСТИЧЕСКОЙ АКТИВНОСТЬЮ ПО ОТНОШЕНИЮ К МУСКАРИНОВОМУ РЕЦЕПТОРУ М3
EA201300186A1 (ru) Бициклические азагетероциклические карбоксамиды
EA201070327A1 (ru) Катехоламиновые производные и их пролекарства

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ BY KZ KG MD TJ TM